Chen Qing-yong, Yan Jie, Hu Hui-zhen, Chen Fang-yuan, Song Jia, Jiang Zhong-yong, Jiao De-min, Wu Yu-quan
Department of Pulmonary Diseases, the 117th Hospital of PLA, Hangzhou 310004, China.
Zhonghua Zhong Liu Za Zhi. 2012 Jun;34(6):436-40. doi: 10. 3760/cma.j.issn.0253-3766.2012.06.008.
To explore the expression of ezrin protein in human non-small cell lung cancer (NSCLC) tissues and lung cancer cell lines, and the association between the expression of ezrin protein and the expression of E-cadherin and CD44V6 proteins.
The expression of ezrin protein and mRNA in lung cancer cell lines was detected by RT-PCR and Western blotting. Ezrin, E-cadherin and CD44V6 were detected by immunohistochemical SP staining in tumor tissues from 150 lung cancer cases and in adjacent normal lung tissues from 30 patients. Furthermore, the expression of ezrin in 30 freshly-taken NSCLC tissues was also detected by Western blot.
The expression of ezrin protein and mRNA was up-regulated in highly metastatic human lung cancer. The positive rate of ezrin, E-cadherin and CD44V6 expression in the lung cancer was 61.3%, 54.0% and 58.7%, respectively. The up-regulation of ezrin expression was significantly correlated with lymph node metastasis, but not correlated with age, sex, tumor size, histological type, clinical TNM system and pathological grade. Western blot analysis showed that the level of ezrin in the NSCLC tissues was significantly higher than that in the normal tissues (t = 5.013, P < 0.01). Survival analysis showed that the 5-year survival rate of patients with negative ezrin expression was 29.3%, significantly higher than that of patients with positive ezrin expression (15.2%, χ(2) = 4.128, P = 0.042). Multivariate Cox regression analysis showed that ezrin expression (RR = 3.012, P = 0.047) and lymph node metastasis (RR = 4.827, P = 0.035) were significantly independent prognostic factors for patients with lung cancer. Furthermore, a negative correlation was observed between the expressions of ezrin and E-cadherin in lung cancer, and a positive correlation between the expressions of ezrin and CD44V6 in lung cancer.
Ezrin, E-cadherin and CD44V6 play an important role in the regulation of growth and meastasis of lung cancer. Combined detection of ezrin, E-cadherin and CD44V6 expression is helpful in evaluating the metastasis and prognosis of non-small cell lung cancer.
探讨埃兹蛋白（ezrin）在人非小细胞肺癌（NSCLC）组织及肺癌细胞系中的表达情况，以及ezrin蛋白表达与E-钙黏蛋白（E-cadherin）和CD44V6蛋白表达之间的关系。
采用逆转录聚合酶链反应（RT-PCR）和蛋白质免疫印迹法检测肺癌细胞系中ezrin蛋白及mRNA的表达。采用免疫组织化学SP法检测150例肺癌患者肿瘤组织及30例患者癌旁正常肺组织中ezrin、E-cadherin和CD44V6的表达。此外，还采用蛋白质免疫印迹法检测30例新鲜采集的NSCLC组织中ezrin的表达。
高转移人肺癌中ezrin蛋白及mRNA表达上调。肺癌中ezrin、E-cadherin和CD44V6表达的阳性率分别为61.3%、54.0%和58.7%。ezrin表达上调与淋巴结转移显著相关，但与年龄、性别、肿瘤大小、组织学类型、临床TNM分期及病理分级无关。蛋白质免疫印迹分析显示，NSCLC组织中ezrin水平显著高于正常组织（t = 5.013，P < 0.01）。生存分析显示，ezrin表达阴性患者的5年生存率为29.3%，显著高于ezrin表达阳性患者（15.2%，χ(2)=4.128，P = 0.042）。多因素Cox回归分析显示，ezrin表达（RR = 3.012，P = 0.047）和淋巴结转移（RR = 4.827，P = 0.035）是肺癌患者显著的独立预后因素。此外，肺癌中ezrin与E-cadherin表达呈负相关，ezrin与CD44V6表达呈正相关。
Ezrin、E-cadherin和CD44V6在肺癌生长和转移调控中起重要作用。联合检测ezrin、E-cadherin和CD44V6表达有助于评估非小细胞肺癌的转移及预后。
